CONSHOHOCKEN, Pa.–(BUSINESS WIRE)–Boomi™, the data activation company for AI, today announced it has been named a Leader in The Forrester Wave™: Adaptive Process Orchestration Software, Q3 2026. The report evaluated 13 providers, and Boomi achieved the highest score in the strategy category. According to the report, Boomi’s “above-par roadmap is driven by a strong internal innovation process that embraces partner input and customer feedback, while recent investments focus on supporting client
Month: September 2026
كونشوهوكين، بنسلفانيا–(BUSINESS WIRE)–أعلنت اليوم شركة Boomi™، المتخصصة في تفعيل البيانات للذكاء الاصطناعي، عن اختيارها كشركة رائدة في تقرير The Forrester Wave™: برمجيات تنسيق العمليات التكيفية، الربع الثالث من عام 2026. قيّم التقرير 13 مزودًا للخدمة، وحققت شركة Boomi أعلى درجة في فئة الاستراتيجية.يتناول هذا البيان الصحفي الوسائط المتعددة. يمكنك الاطلاع على البيان كاملاً هنا: https://www.businesswire.com/news/home/20260928942120/ar/تسمية Boomi كشركة رائدة وتحقيقها أعلى درجة في فئة الاستراتيجية
LONDON–(BUSINESS WIRE)– Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust SMID Rising Dividend Achievers UCITS ETF 25.09.2026 SDVI.LN IE000YVOQ2A3 40,361.00 USD 1,131,026.11 28.023
LONDON–(BUSINESS WIRE)– Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust SMID Rising Dividend Achievers UCITS ETF 25.09.2026 SDVY.LN IE0001R850E1 15,504,007.00 USD 384,146,172.92 24.777
LONDON–(BUSINESS WIRE)– Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Growth Strength UCITS ETF 25.09.2026 FTGS.LN IE000YZLMXT9 25,002.00 USD 599,429.79 23.975
NEW YORK–(BUSINESS WIRE)–Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Lifecore Biomedical, Inc. (NASDAQ: LFCR) to Webster Equity Partners for $6.28 per share in cash plus one non-tradable contingent value right per share. Halper Sadeh encourages Lifecore shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investi
In week 39 Kvika banki hf. purchased 7,095,000 of its own shares at the purchase price ISK 87,665,375. See further details below:
| Date | Time | No. of shares | Share price | Purchase price |
| 21.09.2026 | 09:38:23 | 1,500,000 | 12.1 | 18,150,000 |
| 22.09.2026 | 14:05:40 | 895,000 | 12.425 | 11,120,375 |
| 22.09.2026 | 14:55:02 | 1,000,000 | 12.425 | 12,425,000 |
| 24.09.2026 | 09:31:09 | 1,000,000 | 12.5 | 12,500,000 |
| 24.09.2026 | 11:15:38 | 1,000,000 | 12.45 | 12,450,000 |
| 24.09.2026 | 13:47:49 | 700,000 | 12.35 | 8,645,000 |
| 25.09.2026 | 09:53:16 | 1,000,000 | 12.375 | 12,375,000 |
| Total | 7,095,000 | 87,665,375 |
The trade is in accordance with Kvika‘s buyback programme, announced on 11 September 2026, based on the authorisation of the bank’s Annual General Meeting on 18 March 2026.
Kvika has now purchased a total of 11,195,000 shares under the buyback programme, which corresponds to 0.259% of issued shares in the company. The total purchase price is ISK 137,792,875. Post these transactions Kvika holds 52,931,460 of own shares which corresponds to 1.222% of issued shares.
Buyback under the programme will be limited to an aggregate purchase price of up to ISK 1,540,550,041 and no more than 165,500,003 shares.
The buyback programme will remain in effect until shares have been repurchased for an aggregate consideration of ISK 1,540,550,041 or 165,500,003shares have been acquired, whichever occurs first, but no later than 30 April 2027.
The execution of the buy-back programme must comply with Act on Public Limited Companies. No. 2/1995. In addition. the buy-back programme must be implemented as provided for in the Regulation of the European Parliament and of the Council no. 596/2014. on market abuse. as well as the Commission Delegated Regulation (EU) 2016/1052 on regulatory technical standards for the conditions applicable to buy-back programmes and stabilisation measures. which supplements that Regulation.
Further information please contact Kvika‘s investor relations, ir@kvika.is.
LONDON–(BUSINESS WIRE)– Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Moderate Buffer UCITS ETF – February 25.09.2026 GFEB.LN IE000X8M8M80 700,002.00 USD 28,166,695.10 40.238
VALLOUREC
French limited liability company (société anonyme) with a Board of Directors
with share capital of € 5,343,314.40
Registered office: 12, rue de la Verrerie – 92190 Meudon, France
Registered on the Nanterre Trade and Companies Register under n° 552 142 200
Meudon, September 28th, 2026
Monthly information relating to the total number of voting rights
and shares comprising the share capital
Article L. 233-8-II of the French Code de commerce and
Article 223-16 of the General Regulations of the Autorité des Marchés Financiers (AMF)
| Date | Total number of outstanding shares |
Theoretical total number of voting rights (1) | Net total number of voting rights (2) |
| 31 August 2026 | 267 165 720 | 265 886 457 | 265 269 153 |
| 31 July 2026 | 267 165 720 | 265 886 457 | 265 002 653 |
| 30 June 2026 | 238 699 859 | 237 400 546 | 231 446 001 |
| 31 May 2026 | 238 699 838 | 237 338 263 | 232 248 560 |
| 30 April 2026 | 238 699 838 | 234 651 591 | 229 560 849 |
| 31 March 2026 | 238 407 393 | 234 359 146 | 229 261 460 |
| 28 February 2026 | 238 407 393 | 234 359 146 | 232 314 985 |
| 31 January 2026 | 238 407 393 | 234 359 146 | 234 232 710 |
| 31 December 2025 | 238 407 393 | 234 359 146 | 234 228 327 |
| 30 November 2025 | 238 407 393 | 234 359 146 | 234 225 557 |
| 31 October 2025 | 238 407 393 | 234 359 146 | 233 983 587 |
| 30 September 2025 | 238 407 393 | 234 359 146 | 233 895 369 |
| 31 August 2025 | 238 391 214 | 234 359 146 | 233 880 662 |
| 31 July 2025 | 238 391 214 | 234 359 146 | 233 584 162 |
| 30 June 2025 | 238 391 214 | 234 359 146 | 233 321 151 |
| 31 May 2025 | 238 362 191 | 234 359 146 | 234 059 146 |
| 30 April 2025 | 238 358 136 | 234 253 093 | 234 253 093 |
| 31 March 2025 | 238 139 535 | 234 034 492 | 234 034 492 |
| 28 February 2025 | 238 084 623 | 233 993 941 | 233 993 941 |
| 31 January 2025 | 238 084 623 | 233 966 259 | 233 966 259 |
| 31 December 2024 | 238 084 623 | 233 917 225 | 233 917 225 |
| 30 November 2024 | 238 052 129 | 231 123 100 | 231 123 100 |
| 31 October 2024 | 238 052 129 | 231 051 893 | 231 051 893 |
| 30 September 2024 | 237 784 309 | 230 304 541 | 230 304 541 |
| 31 August 2024 | 237 784 309 | 230 244 702 | 230 244 702 |
| 31 July 2024 | 237 784 309 | 229 947 719 | 229 947 719 |
| 30 June 2024 | 237 271 828 | 229 877 070 | 229 769 402 |
| 31 May 2024 | 237 271 828 | 229 877 070 | 229 769 402 |
| 30 April 2024 | 237 271 828 | 229 877 070 | 229 769 402 |
| 31 March 2024 | 237 271 828 | 229 877 070 | 229 769 402 |
| 29 February 2024 | 237 271 828 | 229 877 070 | 229 769 402 |
| 31 January 2024 | 237 271 828 | 229 877 070 | 229 769 402 |
| 31 December 2023 | 237 271 828 | 229 877 070 | 229 769 402 |
| 30 November 2023 | 236 781 727 | 229 386 969 | 229 279 301 |
| 31 October 2023 | 236 781 727 | 229 386 969 | 229 279 301 |
| 30 September 2023 | 236 635 229 | 229 240 471 | 229 132 803 |
| 31 August 2023 | 236 619 061 | 229 240 471 | 229 132 803 |
| 31 July 2023 | 236 619 061 | 229 240 471 | 229 132 803 |
| 30 June 2023 | 235 532 187 | 229 240 471 | 229 132 803 |
| 31 May 2023 | 231 777 627 | 229 228 999 | 229 080 116 |
| 30 April 2023 | 231 777 627 | 229 228 999 | 229 080 116 |
| 31 March 2023 | 231 777 627 | 229 228 999 | 229 080 116 |
| 28 February 2023 | 231 777 627 | 229 228 999 | 229 080 116 |
| 31 January 2023 | 231 777 627 | 229 228 999 | 229 080 116 |
| 31 December 2022 | 231 777 627 | 229 228 999 | 229 080 116 |
| 30 November 2022 | 231 777 627 | 229 228 999 | 229 080 116 |
| 31 October 2022 | 231 777 627 | 229 228 999 | 229 080 116 |
| 30 September 2022 | 228 928 428 | 228 928 428 | 228 779 545 |
| 31 August 2022 | 228 928 428 | 228 928 428 | 228 779 545 |
| 31 July 2022 | 228 928 428 | 228 928 428 | 228 779 545 |
| 30 June 2022 | 228 928 428 | 228 928 428 | 228 779 502 |
| 31 May 2022 | 228 928 428 | 228 928 428 | 228 740 763 |
| 30 April 2022 | 228 928 428 | 228 928 428 | 228 740 763 |
| 31 March 2022 | 228 928 428 | 228 928 428 | 228 740 763 |
| 28 February 2022 | 228 928 428 | 228 928 428 | 228 740 763 |
| 31 January 2022 | 228 928 428 | 228 928 428 | 228 740 763 |
| 31 December 2021 | 228 928 428 | 228 928 428 | 228 740 763 |
| 30 November 2021 | 228 928 428 | 228 928 428 | 228 740 763 |
| 31 October 2021 | 228 928 428 | 228 928 428 | 228 740 763 |
| 30 September 2021 | 228 928 428 | 228 928 428 | 228 740 763 |
| 31 August 2021 | 228 928 428 | 228 928 428 | 228 740 763 |
| 31 July 2021 | 228 928 428 | 228 928 428 | 228 714 160 |
(1) According to Art. 223- 11 of the AMF General Regulations the theoretical (or gross) number of voting rights is used on the basis of all shares with voting rights, including shares temporarily deprived of voting rights (treasury shares, liquidity contract treasury shares), but excluding shares which have no voting rights (preferred shares).
(2) The net number of voting rights (or voting rights “exercisable at a Shareholders’ Meeting”) is calculated by excluding shares without voting rights. It is provided for public information.
The by-laws of Vallourec contain a provision imposing an obligation to declare crossing thresholds in addition to those relating to legal thresholds.
This information is also available on the Vallourec website under “Regulated information”: https://www.vallourec.com/en/hub-finance/informations-reglementees
Attachment
Company announcement No. 50 / 2026
Zealand Pharma – Transactions related to share buy-back program (week 39, 2026)
Copenhagen, Denmark, September 28, 2026 – Zealand Pharma A/S (“the Company” or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports transactions related to its share buy-back program (the “Program”) for week 39 (September 21 – September 25, 2026).
The Program is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 (the Market Abuse Regulation, “MAR”) and Commission Delegated Regulation (EU) 2016/1052 (the “Safe Harbour Regulation”). Reference is made to company announcement no. 15 / 2026 dated May 7, 2026, which sets out the full terms of the Program. Under the Program, Zealand Pharma may repurchase shares for a total consideration of up to DKK 1.3 billion. The maximum number of shares that may be acquired under the Program is 7,152,557, and the Program commenced on May 7, 2026, and will be completed no later than October 31, 2026. The Company has appointed Danske Bank as lead manager for the Program. Danske Bank will make its own trading decisions independently of, and without influence from, the Company.
Transactions executed in week 39
The following transactions have been executed on Nasdaq Copenhagen (XCSE) under the Program during week 39 (September 21, 2026 – September 25, 2026):
| Date | Number of shares | Average purchase price (DKK) | Transaction value (DKK) |
| Accumulated as per latest announcement | 3,625,000 | 1,088,946,670 | |
| 21/09/2026 | 55,000 | 277.43 | 15,258,650 |
| 22/09/2026 | 60,000 | 277.50 | 16,650,000 |
| 23/09/2026 | 60,000 | 279.69 | 16,781,400 |
| 24/09/2026 | 70,000 | 275.62 | 19,293,400 |
| 25/09/2026 | 70,000 | 274.06 | 19,184,200 |
| Accumulated (W39) | 315,000 | 87,167,650 | |
| Total accumulated under the Program |
3,940,000 | 1,176,114,320 |
Treasury shares and share capital
Following the transactions described above, Zealand Pharma holds a total of 4,810,842 treasury shares, corresponding to approximately 6,72% of the Company’s share capital.
The total number of shares in Zealand Pharma is 71,610,005, each with a nominal value of DKK 1.
Additional information
Detailed information on each transaction executed under the Program is available in the appendix to this company announcement.
About Zealand Pharma
Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health. To date, more than 10 Zealand Pharma invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late-stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization. Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Boston, Massachusetts. Learn more at www.zealandpharma.com.
Contacts
Eric Rojas (Investors)
Vice President, Head of Investor Relations
Zealand Pharma
Email: erojas@zealandpharma.com
Neshat Anis Ahmadi (Investors)
Investor Relations Manager
Zealand Pharma
Email: neahmadi@zealandpharma.com
Rachel James-Owens (Media)
Vice President, Corporate Communications and Media Relations
Zealand Pharma
Email: rjamesowens@zealandpharma.com
Andreas Hylleberg Mølleskov (Media)
Director, External Communications
Zealand Pharma
Email: ahylleberg@zealandpharma.com
Attachment
